Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Eleven patients were initially treated for localized prostate cancer with radical retropubic prostatectomy following negative pelvic lymph node dissection. Six or more months after surgery, these patients had elevated serum prostate specific antigen (PSA) levels. No patient had other clinical evidence of disease as determined by history, physical examination, bone scan, computed tomographic scan of the abdomen and pelvis, chest radiograph, complete blood cell count, and serum chemistry profile. These patients received prostate bed irradiation using 10-MV photons and a four-field technique. Doses ranged from 60.0 to 65.8 Gy in 1.8 to 2.0 Gy fractions. Levels of serum PSA were monitored and decreased initially in all treated patients. In two patients, levels of PSA increased after this initial decrease. In 7 of the 11 patients (64%), PSA levels decreased to less than or equal to 0.3 ng/mL at last measurement. Radiotherapy resulted in no severe toxicity. None of the patients had developed clinical evidence of disease at the time of this report. Isolated elevations of serum PSA after prostatectomy reflect residual disease, and radiotherapy appears to effectively decrease the PSA levels in most cases. This effect appears to be accomplished by killing locally residual or recurrent cancer in the postoperative tumor bed.
 ...
PMID:The results of radiotherapy for isolated elevation of serum PSA levels following radical prostatectomy. 137 60

A series of 245 patients with prostate cancer treated by external irradiation was analysed to assess the impact of irradiation on urinary outlet obstruction. Prior to irradiation, obstruction was observed in 147/245 patients (60%). Irradiation either with or without hormonal therapy was as efficacious as transurethral resection of the prostate (TURP) in alleviating obstructive symptoms; 14/16 patients treated by irradiation alone responded, as did 19/19 who received hormonal therapy and irradiation and 109/112 who underwent TURP and irradiation. Following irradiation, 41/245 patients developed post-irradiation obstruction, 26/213 had post-irradiation strictures and 15/32 developed recurrent cancer. Surgical intervention was required less often for the management of recurrent obstruction caused by stricture as compared with recurrent cancer. TURP and urinary outlet obstruction acted as independent and additive variables to the development of post-irradiation stricture. Thus the avoidance of TURP in patients with obstructive symptoms reduced but did not eliminate the risk of developing a stricture.
 ...
PMID:Prostate cancer--the impact of irradiation on urinary outlet obstruction. 142 90

Metastatic cancer to the penis is rare, its optimum treatment remains poorly defined and the outcome of patients with such metastases is poor. Hyperthermia in conjunction with radiation therapy has been shown to be an effective modality in the treatment of locally advanced or recurrent cancer and hyperthermia alone is under evaluation in treating benign disorders, such as hypertrophy of the prostate. Recently, 4 patients with symptomatic metastatic lesions to the penis (3 had primary prostatic cancer and 1 had rectal cancer) were treated with radiation therapy and hyperthermia. Treatment was well tolerated except for pain during hyperthermia, which limited the temperatures that could be obtained. All of the patients improved symptomatically, 1 achieved a complete response and 2 had partial responses. No significant complications were noted. Symptomatic control was maintained in all patients for the duration of their survival. This limited series suggests the possible role of local hyperthermia as an adjunct to radiation therapy in the treatment of metastases to the penis.
 ...
PMID:Cancer metastatic to the penis: treatment with hyperthermia and radiation therapy and review of the literature. 161 85

Transrectal ultrasonography of the prostate was performed before radical prostatectomy in 22 patients with persistent or recurrent cancer after definitive radiotherapy. Serial transverse sonograms were compared with whole-mount step-sections of the prostatectomy specimens to evaluate the sonographic features of irradiated prostate cancer. To define more clearly the effects of radiation on malignant prostatic tissue, we assessed the degree of histological change induced by the irradiation (radiation effects) as none, mild, moderate or severe. A total of 121 areas of cancer greater than 4 mm in maximum diameter were identified on the histological sections. Of these, 105 (87%) showed no radiation effects or mild effects, and 72% (76/105) of these appeared hypoechoic on the corresponding sonogram. There were 16 foci with moderate or severe radiation effects and only 25% (4/16) appeared hypoechoic. The remaining 12 foci were isoechoic. Areas of cancer which show moderate or severe radiation effects tend to become isoechoic while large (greater than 4 mm) foci of cancer in the irradiated prostate usually show little radiation effect, and these foci typically appear hypoechoic.
 ...
PMID:The sonographic appearance of irradiated prostate cancer. 188 45

During the last 66 months, 482 urinary cytologic examinations were performed on 160 inpatients suspected of having genitourinary cancer at our University Hospital. Cytologic diagnosis was done according to the Papanicolaou's classification. The cytologic findings were compared by size, shape, numbers of the tumor and the histologic findings. The positive rate (classes IV and V) was 56.7% (90 patients) in bladder cancer, 22.2% (18 patients) in prostatic cancer, 13.3% (15 patients) in renal cancer and 62.5% (8 patients) in renal pelvic or ureteral cancer. There was no false positive case for benign disease. The positive rate of cytologic examinations for stage A bladder cancer was statistically lower than that for stage B, C and D cancers. There were no statistically significant differences among the stage B, C and D groups. The positive rate in the low grade (grade I and II) bladder cancer was statistically lower than that of high grade (grade III and IV) cancer. In the small tumor less than thumbtip -sized, cytological diagnosis was positive in 40.0%, while in the large tumor larger than this size, the positive rate was 73.3%. The difference between these two groups was statistically significant. The positive rate in the non-recurrent cases of the bladder cancer was 64.5%, while that in the recurrent cancer cases was 39.3%. The difference between these two groups was statistically significant. The positive rate of urinary cytology did not correspond to the shape or number of tumors. It is desirable to perform cytology more than 3 times on the same patient.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Clinical study of urinary cytology: with special reference to bladder cancer]. 667 8

From 1969 through 1976, we performed cryosurgery in 229 cases of prostatic cancer. Most of these patients had bulky, locally extensive primary tumors, and one-half had disseminated disease. Through the open perineal approach, which gives exposure for an adequate freeze, cryosurgery has been well tolerated. The primary surgical goal has been to reduce or eliminate the local lesion to minimize subsequent cancer-related lower urinary tract problems and to cure those patients with truly localized disease. In every case cryosurgery produced dramatic shrinkage of the local lesion. After four to eight weeks a local recurrence was suspected in 13 per cent, and 41 per cent eventually had some evidence of a recurrent cancer nodule or persistent cancer in the bladder neck. In a series of statistical analyses we have related these recurrences to other clinical factors. Cryosurgery has been a safe, effective way to reduce or eliminate the primary prostatic cancer, even in patients with large local lesions.
 ...
PMID:Cryosurgery in prostatic cancer: elimination of local lesion. 686 58

We reviewed our experience with salvage radical prostatectomy for locally recurrent cancer in 40 patients to assess the current complication rate and the results using prostate specific antigen (PSA) as an indicator of treatment outcome and to identify better criteria for the selection of appropriate candidates for this operation. Most recurrent cancers were detected by digital rectal examination (26 patients) or increasing serum PSA levels (10). The operation was technically challenging, with 6 rectal injuries (15%), 2 requiring temporary colostomy. Serious technical complications were more common (31%) among the 29 patients who underwent pelvic lymphadenectomy at the time of initial radiotherapy than among the 11 treated with external irradiation alone (9%). Urinary incontinence persisted in 18 of 31 evaluable patients (58%) and was successfully corrected with an artificial urinary sphincter in 9. A total of 21 patients (54%) had pathologically advanced disease (seminal vesicle invasion and/or lymph node metastases). Preoperative PSA levels but not clinical stage or biopsy grade correlated with pathological stage (p < 0.03). If the PSA was less than 10 ng./ml. only 15% of the patients had an advanced pathological stage, compared to 86% if the PSA was 10 or more. After 2 to 97 months (mean 39) 2 patients died of metastatic prostatic cancer, 5 had distant metastases and none had symptomatic local recurrence. At 5 years the actuarial nonprogression rate measured by PSA was 55 +/- 20%. The only pretreatment factor predictive of progression was the serum PSA level. If the PSA was less than 10 ng./ml. the actuarial rate of progression was significantly lower than if the PSA was greater than 10 (p < 0.05). The best results were in the subset of 18 patients with cancer confined to the prostate or immediate periprostatic tissue: 82% had no progression at 5 years. Within each of these pathological stages the results of salvage prostatectomy were similar to those for standard radical prostatectomy in patients with no prior irradiation. Although technically challenging, salvage prostatectomy provides excellent control of radio-recurrent cancer confined to the prostate or immediate periprostatic tissue and is best performed before the preoperative PSA level increases to greater than 10 to 20 ng./ml.
 ...
PMID:Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. 754 67

We evaluated the usefulness of an ultrasensitive immunoassay for prostate specific antigen (PSA), modified from the standard Yang Pros-Check PSA test and with a biological detection limit for PSA in serum of 0.07 ng./ml., to detect residual prostate cancer at an earlier date. We studied retrospectively serial frozen serum samples from 22 prostate cancer patients after radical prostatectomy who later had residual cancer with detectable PSA levels of 0.3 ng./ml. or more by the standard PSA test. As controls we studied 33 cystoprostatectomy patients (for bladder cancer) without histological evidence of prostate cancer and 23 patients after radical prostatectomy who had the highest probability of cure of the cancer. All control patients without cancer had PSA values (282 of 283 samples, 99.6%) of less than 0.1 ng./ml. This value was called the residual cancer detection limit. In the 22 patients with recurrent cancer the ultrasensitive assay detected cancer recurrence (PSA 0.1 ng./ml. or more) much earlier (median 202 and mean 310 days) than the standard assay (PSA 0.3 ng./ml. or more). On screening 187 current post-radical prostatectomy patients without evidence of cancer by the standard assay the ultrasensitive assay detected 21 (11.2%) with evidence of residual cancer, that is PSA level of 0.1 ng./ml. or more. We conclude that an ultrasensitive assay for PSA can detect residual cancer after radical prostatectomy much earlier than current immunoassays for PSA. Earlier detection of residual cancer may improve long-term survival by allowing for earlier institution of adjuvant therapy.
 ...
PMID:Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen. 768 Nov 19

We treated three brothers for prostate cancer. The first brother developed the disease of poorly differentiated adenocarcinoma at the age of 76, and was treated with endocrine therapy but died of recurrent cancer at age 80. The second brother was diagnosed poorly differentiated adenocarcinoma at age 75, and he is alive at age 80 without recurrence after endocrine therapy. The third brother developed moderately differentiated adenocarcinoma at age 58, and was treated with endocrine therapy but died of recurrent cancer at age 73. We have seen few familial cases of prostate cancer. The first such case is reported here in Japan. Eleven similar cases of familial prostate cancer involving three or more brothers have been reported in the Western literature.
 ...
PMID:[A familial case of prostate cancer in three brothers]. 780 77

To estimate the probabilities of complications and follow-up treatment, a sample of Medicare patients who underwent radical prostatectomy (1988 through 1990) was surveyed by mail, telephone, and personal interview. Respondents reported their current status with respect to continence and sexual function as well as post-surgical treatments they had had to treat residual or recurrent cancer or surgical complications. Over 30 percent reported currently wearing pads or clamps to deal with wetness; over 40 percent said they drip urine when they cough or when their bladders are full; 23 percent reported daily wetting of more than a few drops. About 60 percent of patients reported having no full or partial erections since their surgery, and only 11 percent had any erections sufficient for intercourse during the month prior to the survey. Six percent had surgery after the radical prostatectomy to treat incontinence; 15 percent had treatments or used devices to help with sexual function; 20 percent report having had post-surgical treatment for urethral strictures. In addition 16 percent, 22 percent, and 28 percent reported follow-up treatment for cancer (radiation or androgen deprivation therapy) at two, three, and four years after radical prostatectomy. These estimates of complication and follow-up treatment rates are generally higher, and almost certainly more representative for older men, than estimates previously published. Patients and physicians may want to weight heavily the complications and need for follow-up treatments when considering radical prostatectomy for prostate cancer.
 ...
PMID:Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). 825 94


1 2 3 4 5 Next >>